Form 8-K - Current report:
SEC Accession No. 0001213900-21-063497
Filing Date
2021-12-06
Accepted
2021-12-06 08:15:36
Documents
14
Period of Report
2021-12-06
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea151751-8k_180lifesci.htm   iXBRL 8-K 34378
2 PRESS RELEASE DATED DECEMBER 6, 2021 ea151751ex99-1_180lifesci.htm EX-99.1 15288
  Complete submission text file 0001213900-21-063497.txt   277996

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE atnf-20211206.xsd EX-101.SCH 3790
4 XBRL DEFINITION FILE atnf-20211206_def.xml EX-101.DEF 26659
5 XBRL LABEL FILE atnf-20211206_lab.xml EX-101.LAB 36698
6 XBRL PRESENTATION FILE atnf-20211206_pre.xml EX-101.PRE 25277
7 EXTRACTED XBRL INSTANCE DOCUMENT ea151751-8k_180lifesci_htm.xml XML 5704
Mailing Address 830 MENLO AVENUE, SUITE 100 MENLO PARK CA 94025
Business Address 830 MENLO AVENUE, SUITE 100 MENLO PARK CA 94025 650-507-0669
180 Life Sciences Corp. (Filer) CIK: 0001690080 (see all company filings)

EIN.: 813832378 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38105 | Film No.: 211472072
SIC: 2834 Pharmaceutical Preparations